Paclitaxel poliglumex cell therapeutics/Chugai Pharmaceutical

IDrugs

Volumn 8, Issue 9, 2005, Pages 739-754

  Man, Martha ^a   Rugo, Hope ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CATHEPSIN B; CHC 12103; CISPLATIN; CT 2106; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GROWTH FACTOR; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM DERIVATIVE; POLYGLUTAMIC ACID; STEROID; TAXANE DERIVATIVE; TENIPOSIDE; TRITIUM; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALOPECIA; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST TUMOR; CANCER CENTER; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED RELEASE FORMULATION; DEHYDRATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; IC 50; INFECTION; LICENCE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MICROTUBULE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY TUMOR; PATENT; SENSORY NEUROPATHY; SEPSIS; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; POLYGLUTAMIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 24644433861     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. 197619 Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A J MED CHEM 1996 39 2 424-431
2. 271554 Preclinical antitumor activity of water-soluble peciltaxel derivatives. Rose WC, Clark JL, Lee FYF, Casazza AM CANCER CHEMOTHER PHARMACOL 1997 39 6 486-492
3. 302934 Cell Therapeutics Inc - technology platforms and product portfolio. Cell Therapeutics Inc COMPANY BROCHURE 1996 14 10
4. 324068 Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Li C, Price JE, Milas L, Hunter NR, Ke S, Tansey W, Charnsagavej C, Wallace S PROC AM ASSOC CANCER RES 1999 40 Abs 1909
5. 352896 Cell Therapeutics initiates clinical trial with novel taxol - patented polymer technology may revolutionize how cancer patients are treated. Cell Therapeutics Inc PRESS RELEASE 2000 January 19
6. 36868 Synthesis of congeners and produgs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. Deutsch HM, Glinski JA, Hernandez M, Haugwitz RD, Narayanan VL, Suffness M, Zalkow LH J MED CHEM 1989 32 4 788-792
7. 36969 Synthesis and evaluation of some water-soluble produgs and derivatives of taxol with antitumor activity. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ J MED CHEM 1992 35 1 145-151
8. 391074 Pharmacokinetic (PK) and biodistribution of poly-(L)-glutamic acid (PG) paclitaxel (TXL) (CT-2103) in mice with subcutaneous B-16 melanomas. de Vries P, Bellamy G, Nudelmann E, Brannan M, Lewis RA, Singer JW, Baker B NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 November 7-11 Abs 555
9. 404066 CT-2103: A water soluble poly-L-glutamic acid (PG)- paclitaxel (TXL) conjugate has enhanced efficacy on MDR-1+ human colon carcinoma cell xenografts compared to free TXL. de Vries P, Kumar A, Heasley E, Stone I, Singer J PROC AM ASSOC CANCER RES 2001 42 Abs 462
10. 410069 Phase I and pharmacological study of CT-2103, a poly (L-glutamic acid)-paclitaxel conjugate. Todd R, Sludden J, Boddy AV, Griffin MJ, Robson L, Cassidy J, Bissett D, Main M, Brannan MD, Elliott S, Fishwick K et al PROC AM SOC CLIN ONCOL 2001 20 Pt 1 Abs 439
11. 426502 Licensing agreement on new anti-cancer agent belonging to the taxoid family, 'polyglutamate paclitaxel'. Chugai Pharmaceutical Co Ltd PRESS RELEASE 2001 October 22
12. 431955 Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Li C, Yu DF, Newman RA, Carbal F, Stephens LC, Hunter N, Milas L, Wallace S CANCER RES THERAPY CONTROL (1998) 58 11 2404-2409
13. 446509 Metabolism of poly-L-glutamic acid (PG) paclitaxel (CT-2103); proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Shaffer SA, Lee CB, Nudelman E, Kumar A, Coon M, Stone I, DeVries P, Singer JW PROC AM ASSOC CANCER RES 2002 43 Abs 2067
14. 452418 A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Sabbatini P, Brown J, Aghajanian C, Hensley ML, Pezzulli S, O'Flaherty C, Lovegren M, Funt S, Warner M, Mitchell P, Bolton MG PROC AM SOC CLIN ONCOL 2002 21 1Abs 871
15. 453219 Phase II study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-contaning regimen. Schulz J, Burris HA, Redfern C, Mitchell P, Warner M, Bolton MG PROC AM SOC CLIN ONCOL 2002 21 1 Abs 2330
16. 454818 Investigators report encouraging responses with XYOTAX in patients with chemotherapy resistant cancers. Cell Therapeutics Inc PRESS RELEASE 2002 June 15
17. 455580 Cell Therapeutics Inc to make milestone payment following completion of enrollment in phase II ovarian clinical trial of XYOTAX. Cell Therapeutics Inc PRESS RELEASE 2002 June 20
18. 459857 Cell Therapeutics Inc initiates first phase II XYOTAX study in breast cancer. Cell Therapeutics Inc PRESS RELEASE 2002 August 01
19. 465164 Lung cancer experts to lead Cell Therapeutics Inc's XYOTAX phase III trials. Cell Therapeutics Inc PRESS RELEASE 2002 September 25
20. 466099 Cell Therapeutics Inc initiates phase III clinical trial of XYOTAX for second-line treatment of non-small cell lung cancer. Cell Therapeutics Inc PRESS RELEASE 2002 October 07
21. 470061 Cell Therapeutics Inc earns $3 million milestone payment. Cell Therapeutics Inc PRESS RELEASE 2002 November 13
22. 470668 Pharmacological study of CT-2103 (XYOTAX™), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study. Boddy A, Todd R, Verrill M, Sludden J, Fishwick K, Robson L, Cassidy J, Bisset D, Garzone PD, Calvert AH AACR NCI EORTC MOL TARGETS CANCER THER 2002 38 19-22 November Abs 98
23. 471373 Phase I study of XYOTAX (CT-2103) and cisplatin in patients with solid tumors: Preliminary data. Kudelka AP, Skubitz K, Kavanagh J, Garzone PG, Bolton MG AACR NCI EORTC MOL TARGETS CANCER THER 2002 19-22 November Abs 436
24. 471530 Encouraging Interim phase II data of XYOTAX in front-line treatment of non-small cell lung cancer. Cell Therapeutics Inc PRESS RELEASE 2002 November 22
25. 471726 Encouraging phase I clinical data of XYOTAX and cisplatin presented at International Conference. Cell Therapeutics Inc PRESS RELEASE 2002 November 25
26. 476468 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Maeda H, Matsumura Y, Wu J, Sawa T, Hori K J CONTROL RELEASE 2000 65 1-2 271-284
27. 485158 Chugai - development pipeline. Chugai Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2003 April 10 http://www.chugai-pharm.co.jp
28. 488996 Poly(L-glutamic acid)-paclitaxel conjugate is a patent enhancer of tumor radiocurability. Milas L, Mason KA, Hunter N, Li C, Wallace S INT J RADIAT ONCOL BIOL PHYS 2003 55 3 707-712
29. 489004 Potentiation of radioresponse by polymer-drug conjugates. Ke S, Milas L, Charnsangavej C, Wallace S, Li C J CONTROL RELEASE 2001 74 1-3 237-242
30. 489009 Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S CLIN CANCER RES 2000 6 7 2829-2834
31. 489010 Potentiation of ovarian OCa-1 tumor radioresponse by poly(L-glutamic acid)-paclitaxel conjugate. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S INT J RADIAT ONCOL BIOL PHYS 2000 48 4 1119-1126
32. 489011 Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S CANCER CHEMOTHER PHARMACOL 2000 46 5 416 422
33. 489014 Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Oldham EA, Li C, Ke S, Wallace S, Huang P INT J ONCOL 2000 16 1 125-132
34. 489021 Paclitaxel and water-soluble poly(L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Multani AS, Li C, Ozen M, Yadav M, Yu DF, Wallace S, Pathak S ANTICANCER RES 1997 17 6D 4269-4274
35. 491164 Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors. Verrill MW, Boddy AV, Todd R, Verrill M, Sludden J, Fishwick K, Robson L, Cassidy J, Bissett D, Calvert H PROC AM SOC CLIN ONCOL 2003 22 Abs 533
36. 491443 Phase 2 study of first line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are 70 years of age or performance status (PS) = 2. Norton MS, Neubauer M, Harper H, Bolton MG PROC AM SOC CLIN ONCOL 2003 22 Abs 2626
37. 491816 A phase 2 study of CT-2103, 8 poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer. Robson R, Verrill M, Lind M, Simmons P, Perren T, Coombes C, Earl H, Calvert H, Campbell M, Bolton MG PROC AM SOC CLIN ONCOL 2003 22 Abs 169
38. 492279 Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen. Schulz JJ, Burris HA, Redfern C, Bolton MG PROC AM SOC CLIN ONCOL 2003 22 Abs 1137
39. 493442 Phase I study of CT-2103/carboplatin in patients with solid tumors. Bolton MG, Nemunaitis J PROC AM SOC CLIN ONCOL 2003 22 Abs 646
40. 493630 Phase I study of CT-2103 in patients with non-small cell lung cancer. Shipley D, Greco A, Jones S, Willcutt N, Garzone P, Bolton MG, Burris HA PROC AM SOC CLIN ONCOL 2003 22 Abs 2833
41. 493688 Tranzyme announces issuance of new patent protecting key intellectual property for company's functional biology platform. Tranzyme Inc PRESS RELEASE 2003 June 16
42. 509603 Cell Therapeutics Inc amends XYOTAX dose in STELLAR 4 trial. Cell Therapeutics Inc PRESS RELEASE 2003 October 20
43. 515688 Cellular metabolism of poly-L-glutamic acid-paclitaxel (XYOTAX) is mediated in part by lysosomal cathepsin B. Shaffer SA, Lee CB, Lai MS, Kennedy J, Adams K, Ap S, Coon M, Thompson J, Anderson M, Stone I, De Vries P et al CLIN CANCER RES 2003 9 16 Suppl 1 Abs C237
44. 530135 Cell Therapeutics Inc and GOG sign landmark agreement for phase III XYOTAX trial. Cell Therapeutics Inc PRESS RELEASE 2004 April 01
45. 547770 GOG submits Investigational New Drug (IND) application and special protocol assessment (SPA) to FDA for pivotal trial of XYOTAX™ in ovarian cancer. Cell Therapeutics Inc PRESS RELEASE 2004 July 07
46. 551068 Cell Therapeutics Inc posts highest TRISENOX(R) sales revenues since product launch. Cell Therapeutics Inc PRESS RELEASE 2004 July 27
47. 577087 San Antonio Breast Cancer Symposium - 27th Annual Meeting, San Antonio, TX, USA. IDDB MEETING REPORT 2004 December 08-11
48. 582831 Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld A et al J CLIN ONCOL 2004 22 22 4523-4531
49. 590999 GOG initiates landmark phase III trial of XYOTAX™ in ovarian cancer. Cell Therapeutics Inc PRESS RELEASE 2005 March 22
50. 599008 STELLAR 2 and 4 pivotal trials demonstrate XYOTAX™ produces equivalent survival while significantly reducing serious side effects in the treatment of first- or second-line non-small cell lung cancer. Cell Therapeutics Inc PRESS RELEASE 2005 May 02
51. 599062 Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer. Takimoto CH, Schwartz G, Romero O, Patnaik A, Tolcher A, Garrison M, Oldham FB, Bernareggi A, Rowinsky E PROC AM SOC CLIN ONCOL 2005 24 Abs 2043
52. 604766 Phase II study of paclitaxel poliglumex/carboplatin for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. Herzog T, Barret RJ, Edwards R, Oldham FB PROC AM SOC CLIN ONCOL 2005 24 Abs 5012
53. 604774 Paclitaxel poliglumex/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study. Langer CJ, Socinski A, O'Byrne KJ PROC AM SOC CLIN ONCOL 2005 24 Abs LBA7011
54. 604778 Paclitaxel poliglumex and concurrent radiation for treatment of patients with esophageal or gastric cancer: A dose-ranging study. Dipetrillo TA, Chauhan B, Akerman P, Ng T, Miner T, Cruff D, Rich T, Oldham FB, Countouriotis A, Safran H PROC AM SOC CLIN ONCOL 2005 24 Abs 4065
55. 606267 Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogensic compartmental models of human ovarian carcinoma. Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, Klostergaard J CLIN CANCER RES 2002 8 2 573-581
56. 606276 Poly (L-glutamic acid)-anticancer drug conjugates. Li C ADV DRUG DELIV REV 2002 54 695-713
57. 606279 Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Maeda H, Seymour LW, Miyamoto Y BIOCONJUG CHEM 1992 3 5 351-362
58. 606284 Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Veronese ML, Flaherty K, Kramer A, Konkle BA, Morgan M, Stevenson JP, O'Dwyer PJ CANCER CHEMOTHER PHARMACOL 2005 55 5 497-501
59. 606286 Proteolysis of XYOTAX by lysosomal cathepain B; metabolic profiling in tumor cells using LC-MS. Shaffer SA, Baker Lee C, Kumar A, Singer JW AACR NCI EORTC MOL TARGETS CANCER THER 2002 Abs 428
60. 606288 Dilemmas in management: The controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (XYOTAX). Langer CJ ONCOLOGIST 2004 9 4 398-405
61. 611212 Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A CLIN PHARMACOKINET 2003 42 7 665-685
62. 611235 Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug. Li C, Yu D, Inoue T, Yang DJ, Milas L, Hunter NR, Kim EE, Wallace S ANTICANCER DRUGS 1996 7 6 642-648
63. 611237 What does multidrug resistance mean in the clinic? Duhem C, Ries F, Dicato M ONCOLOGIST 1996 1 3 151-158
64. 611239 Weekly paclitaxel: An effective and well tolerated treatment in patients with advanced breast cancer. Luck HJ, Roche H CRIT REV ONCOL HEMATOL 2002 44 S15-S30
65. 611240 A phase I study at paclitaxei poliglumex (PPX) in combination with cisplatin (CIS) for patients with advanced cancer. Skubitz KM, Verschraegen CF, Daud A, Bernareggi A, Oldham FB PROC AM SOC CLIN ONCOL 2005 24 Abs 2089
66. 611243 Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary data. Nemunaitis JJ, Leighl N, Miller W, Cormier Y, Bernareggi A, Oldham F PROC AM SOC CLIN ONCOL 2005 24 Abs 7230
67. 611244 Taxane-Induced alopecia: A historical review of patients with ovarian or breast cancer treated with paclitaxel, docetaxel or paclitaxel poliglumex. Calhoun EA, Welshman E, Brown S PROC AM SOC CLIN ONCOL 2005 24 Abs 8044
68. 612811 About CTI: Collaborations. Cell Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2005 July 18 http://www.cticseattle.com/search.asp?navEvent=Top&target= collaboration